In the pathophysiology of bipolar disorders (BD), several lines of evidence support the hypothesis of an underlying dysfunction of the serotonergic system. Increased platelet serotonin (5-hydroxytryptamine or 5-HT), a lower maximal velocity (Vmax) of 5-HT platelet uptake and decreased central serotonergic neurotransmitter activity, indicated by decreased 5HIAA/5-HT ratios, have been reported in untreated bipolar depressed patients (Wirz Justice and Puhringer 1978; Marazziti et al.1991; Leake et al. 1991; Young et al. 1994) . Polymorphism in the 5-HT-transporter, 5-HT receptors and the tryptophan hydroxylase gene have been associated with the pathophysiology of BD (Kunugi et al. 1997; Oruc et al. 1997; Bellivier et al. 1998) .
In the pathophysiology of bipolar disorders (BD), several lines of evidence support the hypothesis of an underlying dysfunction of the serotonergic system. Increased platelet serotonin (5-hydroxytryptamine or 5-HT), a lower maximal velocity (Vmax) of 5-HT platelet uptake and decreased central serotonergic neurotransmitter activity, indicated by decreased 5HIAA/5-HT ratios, have been reported in untreated bipolar depressed patients (Wirz Justice and Puhringer 1978; Marazziti et al.1991; Leake et al. 1991; Young et al. 1994) . Polymorphism in the 5-HT-transporter, 5-HT receptors and the tryptophan hydroxylase gene have been associated with the pathophysiology of BD (Kunugi et al. 1997; Oruc et al. 1997; Bellivier et al. 1998) .
Acute tryptophan depletion (ATD) is a direct method to investigate central serotonergic vulnerability (Delgado et al. 1994) . In this procedure, a lowering of central 5-HT synthesis is accomplished by giving subjects a 50-100 g balanced amino acid-drink (AA-drink), composed of amino acids, including large neutral amino acids (LNAAs: tyrosine, valine, leucine, isoleucine and phenylalanine), and devoid of tryptophan (Trp) (Young 1991) . In remitted depressed patients, ATD induced depressive symptoms (Smith et al. 1997; Aberg-Wistedt et al. 1998; Moreno et al. 2000) . In healthy first-degree relatives of depressed patients, ATD induced a modest lowering of mood, compared with healthy control subjects (Benkelfat et al. 1994; Klaassen et al. 1999) . It thus appears that individuals without prior depressive episodes, but at a genetic risk for depression, may be biologically predisposed to mood-lowering effects of ATD.
Until now, little attention has been paid to the effects of ATD in BD, and results are inconsistent . Cappiello et al. (1997) reported a significant increase in manic symptoms in recently remitted (one month) lithium-treated manic patients. In BD patients who were stable for a longer period (1-15 years), ATD did not induce significant mood changes (Benkelfat et al. 1995; Cassidy et al. 1998; Hughes et al. 2000) .
In BD patients abnormalities in cortisol homeostasis has been described. Cortisol may therefore be used as a biological marker of BD. Serotonin increases cortisol release by stimulating 5-HT 1A and 5-HT 2A receptors in hippocampal areas (Nurnberger et al. 1990; Swann et al. 1992; Vieta et al. 1999) . Changes in cortisol following challenge with selective 5-HT stimulating agents are possible biological markers to assess brain 5-HT function (Abel and Cleare 1999; Cleare et al. 1998) . A blunted cortisol response following an intravenous Trp challenge in BD patients, as compared with controls, provides evidence for brain 5-HT dysfunction (Nurnberger et al. 1990 ). To our knowledge, the effects of ATD on stress-induced cortisol release have never been described, but might provide an important indicator of central 5-HT vulnerability. Symptoms (according to DSM IV) of BD psychopathology might contribute to effects of ATD. Therefore we differentiated between relatives of BD type I and BD type II patients. This study is the first family history (FH) study of 5-HT vulnerability in which such a distinction was made between first-degree relatives of type I (FH I) and type II BD (FH II) patients.
To gain additional insight into the nature of this biological vulnerability, the current study investigated serotonergic vulnerability, as reflected in mood and cortisol responses to ATD in healthy first-degree relatives of BD patients (FH). ATD effects in FH subjects were compared with those in healthy matched controls. We hypothesized central serotonergic vulnerability in FH subjects to be reflected by: (1) an elevation in mood, as has been reported in BD patients; (2) more pronounced blunting of stressinduced cortisol release following ATD compared with controls; and (3) mood and cortisol effects of ATD were hypothesized to be different in FH I and FH II subjects.
METHODS

Subjects
Subjects were first-degree relatives of BD patients and healthy matched controls (see Table 1 ). Family members were recruited through BD patients in treatment at the Department of Psychiatry, University Hospital Maastricht, by the consumer organization for manicdepressive patients and their families, and by advertisements in local newspapers. Healthy control subjects were also recruited by a newspaper advertisement.
Of the 47 subjects who enrolled in the study, 2 subjects in the FH group were excluded during the experiment because of intolerance of the drink.
The included subjects were 30 FH (8 men and 22 women) and 15 controls (4 men, 11 women), aged 19-64 years. Table 1 shows demographic characteristics of all subjects who completed the experiment. Relatives were daughters (n ϭ 11), sons (n ϭ 4), siblings (n ϭ 4), mothers (n ϭ 8) and fathers (n ϭ 3). Nineteen subjects had a first-degree relative with a BD type I diagnosis, and eleven subjects were relatives of BD type II patients. Control subjects were successfully matched to FH subjects with respect to age, body mass index (BMI) and intelligence quotient (IQ). There were no differences between FH subjects and controls with respect to number of premenopausal versus postmenopausal women or to use of oral anticonceptives or other medication. Overall, 22 female subjects were premenopausal and 11 were postmenopausal. Seven women used oral anticonceptives. Seven subjects were taking medication with no interference on ATD or cortisol. 
Design
The study used a placebo-controlled, double blind, crossover design. The within subjects-factor, treatment condition, consisted of 2 levels: placebo and ATD. The order of treatment was balanced over two test days, spaced one to two weeks apart. The between-subjects factor FH differentiated subjects with (FH) or without (controls) at least one first-degree relative with BD. A further distinction was made between having a relative with a type I or type II BD (FH I vs. FH II).
To eliminate possible bias due to premenstrual symptoms, all premenopausal women were tested in the follicular phase of the menstrual cycle (Menkes et al. 1994; Rasgon et al. 2000) .
Amino Acid Mixtures
The Trp-deficient AA-drink contained a total of 75 g of different amino acids with the amounts of each specific amino acid according to the proportions described by Young et al. (1985) 
The placebo mixture contained the same amino acids, plus 3.0 g tryptophan. To provide caloric energy, 20 g of a maltodextrin (MD/ fat mix) (33% sunflower and 67% maltodextrin) was added. Both drinks were prepared by adding 300 ml tap water with the addition of strawberry or banana flavoring to compensate for the unpleasant taste (see also Schmitt et al. 2000) .
Procedure
Subjects. In the FH group, the main inclusion criterion was having at least one first-degree relative with BD. Control subjects were free of any psychopathologic family loading. To assess FH, all subjects were interviewed with an abbreviated version of the Family History Research Diagnostic Criteria (FHRDC) (Endicott et al. 1975) . Individual diagnoses (type I or type II BD, according to DSM IV) of the patients were verified via each patient's own psychiatrist.
All participants were given a standardized psychiatric examination (Mini International Neuropsychiatric Interview; MINI) (Sheehan et al. 1994) to determine the present psychiatric state, according to DSM IV criteria. The 17-item Hamilton Depression Rating Scale (HDRS) (Hamilton 1967 ), the Young Mania Rating Scale (YMRS) (Young et al. 1978 ) and the SCL-90 (Arrindell and Ettema 1986) were used to verify the absence of depressive, manic and general psychiatric symptomatology. As an extra check on psychopathology, all subjects filled out the General Behavior Inventory (GBI), which identifies lifetime sub-clinical affective symptoms (Depue et al. 1981 (Depue et al. , 1985 (Depue et al. , 1989 Klein et al.1986 ). Included control and FH subjects did not differ on GBI scores, which meant that they were successfully matched (see Table 1 ).
Exclusion criteria were current or past use of psychopharmacological medication, lifetime psychiatric disorder including alcohol or drug abuse, current active physical illness, lactation and pregnancy. Physical health was assessed by means of a health questionnaire, a standard physical examination by a physician and a urine screening. The urine test (Combur®) included assessment of leukocytes, nitrite, pH, protein, glucose, ketones, urobilinogen, bilirubin and erythrocytes. A Quick View one-step pregnancy test (Quidel®) was carried out in female subjects to check for unsuspected pregnancy.
One control subject was matched with two FH subjects with respect to sex, age, BMI and IQ. Intelligence (IQ) was estimated using Groninger Intelligence Test (GIT) subtasks (Vocabulary, Mental Rotation, Mental Arithmetic and Word Analogies) (Luteijn 1966) .
The Medical Ethics Committee of the Academic Hospital of Maastricht approved the study. All participants gave written informed consent.
The Test Days.
On each test day, the subjects arrived at 8:30 A . M . after an overnight fast. At 10:00 A . M . (t 0 ) (all timepoints t (-)X refer to a time x hours (before) after t 0 ) the subjects were administered the AA-drink, which had to be consumed within two hours. At t 2 , all subjects ate a protein-poor lunch which consisted of protein-free bread, tomatoes, marmalade, apples, oranges and herbal tea or decaffeinated coffee.
Mood assessment was completed at baseline at 8:45 A . M . (t Ϫ 1.25 Q5 ), and at t 5 and t 7 . The stress-inducing speech task (SIST) started at t 6.75 , when the effects of ATD were expected to be present. Three baseline cortisol measurements were collected before the SIST, at t 5 , t 6.5 and t 6.75 . After the SIST, saliva cortisol samples were taken every 15 minutes; at t 7 , t 7.25 , t 7.5 and finally at t 7.75 . Previous studies (van Eck et al. 1996) showed cortisol response to the SIST to be maximal during this time interval.
Blood samples were taken twice, at t 0 and at t 6.5 . Blood pressure and pulse rate were assessed before mood rating at t 0 , and at t 5 .
Mood Assessments
Mood was assessed with the abbreviated bimodal Profile of Mood States (POMS) (McNair et al. 1971 ) and the Bond and Lader (B&L) (Bond and Lader 1974) visual analog scales.
The POMS consists of 32 bipolar sets of adjectives, which measure five mood dimensions: anger, depression, fatigue, tension and vigor.
The B&L is composed of 16 mood items, which measure alertness, contentment, and calmness.
Stress-inducing Speech Task
The SIST consisted of a 5-min oral presentation, in front of a video-camera, preceded by 10 min of preparation. In a slightly modified version of the task used by van Eck et al. (1996) , subjects were first given a list of four mood terms. Three parallel versions of the list were available. Subjects were instructed to elaborate on personal experiences evoked by these mood terms and were told that the speech would be video-recorded for later evaluation by a panel of psychiatrists and psychologists (van Eck et al. 1996; Nicolson et al. 1997) . After the screening a SIST practice session, in which an identical version of the mood term list was used. At the end of the second test day subjects were debriefed.
Salivary Cortisol Measurements
Saliva was collected with a cotton roll (Salivette ®, Sarstedt). Uncentrifuged samples were stored at Ϫ 20 Њ C until analysis. Free cortisol levels were determined in duplicate by direct radioimmunoassay, using a highperformance liquid chromatography high performance liquid chromatography (HPLC)-purified preparation of cortisol-3-CMO-histamine 
Somatic Side Effects
Severity of side effects was determined by a questionnaire with 17 items rated on 4-point scales. The total sum of reported complaints represents the overall severity of side effects.
Serum Amino Acids
Serum was taken by venipuncture in sodium heparin tubes. Blood samples were immediately set on ice and centrifuged (3000 rpm, 10 min) within one hour. Plasma samples were mixed with sulfasalicyl acid and frozen at Ϫ 80 Њ C until analysis. Total concentrations of plasma Trp and ratio of Trp:LNAAs were determined by HPLC (van Eijk et al. 1993 ).
Statistical Analysis
Outcome variables were analyzed using General Linear Model (GLM) for repeated measures. Within-subjects factor was treatment (two levels: ATD or placebo); the between-subjects factor was family history (three levels: controls, FH I, or FH II). Univariate contrasts were used to test the primary hypothesis of difference between controls and FH subjects (controls vs. FH I ϩ II) as well as the hypotheses of differences between controls and FH I and FH II relatives separately (controls vs. FH I and controls vs. FH II). Differences in baseline values between test sessions were assessed using GLM. When no baseline differences were found, baseline values were left out of analyses.
Cortisol values were 10 log-transformed prior to statistical testing, since cortisol distributions were skewed. Missing values were corrected by using mean of previous and next cortisol values. Wilcoxon Matched-Pairs Signed-Ranks Test was used to test differences in physical complaints. Statistical analyses were performed with SPSS 9.0 for Windows.
RESULTS
Plasma Trp Levels
Due to procedural difficulties 1.4% of serum samples were missing.
Plasma Trp concentrations and ratio Trp:LNAAs did not differ at baseline between groups or treatment conditions, but decreased significantly [F 1,28 ϭ 151.11, p Ͻ .001] over time in the ATD condition. Relative to baseline, ATD resulted in a 57% decrease in plasma Trp and a 70% decrease in ratio Trp:LNAAs. After receiving placebo, there was a 36% increase in plasma Trp and 1.0% increase in the ratio Trp:LNAAs. Results are summarized in Figure 1 .
Subjective Mood Ratings
One subject was excluded from the analyses due to 2 missing POMS scores.
At baseline, POMS scores did not differ significantly between FH and controls or experimental conditions. Figure 2 shows the mood response after ATD compared with placebo. Controls and FH I did not differ in ATD induced mood response, but compared with these groups, FH II subjects reported an overall improvement in mood, indicated by the POMS total score [F 2,40 ϭ 3.35, p Ͻ .05], a decrease in fatigue [F 2,40 ϭ 3.65, p Ͻ .05] and a trend toward lower anger [F 2,40 ϭ 3.13, p Ͻ .1]. This is an overall effect; within each FH group mood changes following ATD were not significant. There was no main effect of ATD, overall interaction effect of FH with ATD, or effect of treatment order.
Scores on B&L subscales did not differ at baseline and after ATD between experimental conditions or FH groups.
Cortisol Measurements
Cortisol Response to the SIST. In both ATD and placebo conditions, cortisol levels increased over time in response to the SIST [F 6,36 ϭ 3.60, p Ͻ .05]. A cortisol peak occurred immediately after the speech (t 7 ). Compared with prespeech levels (t 5 ), cortisol was increased by a mean of 21%. The three groups did not differ in pre-speech cortisol levels or in the magnitude of the SIST-induced cortisol response. Figure 3 shows the effect of ATD on cortisol release compared with placebo (the cortisol values in the placebo condition were subtracted). In FH subjects (both FH I and FH II), ATD resulted in a significant decrease in cortisol [F 1,28 ϭ 5.26, p Ͻ .05] compared with placebo. In controls, cortisol was higher after ATD compared with placebo. There were no effects of treatment order.
Effects of ATD.
Of the 630 cortisol samples, 0.4% were missing; two subjects (one FH and one control) were not included in cortisol data analyses, because of extremely high cortisol levels (above 44 nmol/l) probably in response to difficulties in taking blood.
Somatic Side Effects. Sum of reported side effects did not differ at baseline or between the two experimental conditions. Correlation analysis of B&L and POMS mood ratings with side effects revealed no significant correlations of sum complaints with mood changes following ATD.
Intercorrelations
Pearson's correlation analyses showed no significant associations between ATD-induced cortisol response and changes in mood ratings. Effect (mean ϮSE) of type BD (C, control subjects; first-degree relatives; FH I and FH II subjects) and ATD on POMS total score at t 5 and t 7. Values are corrected for placebo (P).
DISCUSSION
The aim of the study was to investigate central 5-HT vulnerability in first-degree relatives of BD patients following a double-blind placebo-controlled ATD paradigm. Plasma ratio Trp:LNAAs and Trp decreased significantly, which indicates an adequate ATD. Tyrosine availability did not appear to have interfered with the effects of ATD, as levels did not differ between experimental conditions. We found no overall differences between controls and FH subjects in ATD-induced mood response. However, FH II subjects reported a tendency to mood elevation, whereas FH I subjects and controls experienced a slight mood lowering following ATD. Side effects were unlikely to have interfered with mood changes after ATD, as the sum of reported side effects did not differ between ATD and placebo.
There are no studies available that describe effects of ATD on different types of BD. Our results are in line with a previous report of elevated mood following ATD in recently remitted BD patients, who were not further differentiated as type I or type II (Cappiello et al. 1997) .
Previous studies of ATD in BD patients suggest that BD patients who were recently in remission were more vulnerable to the effects of ATD compared with BD patients who were in remission for a longer period (Benkelfat et al. 1995; Cappiello et al. 1997) . It was suggested that successful short-term lithium treatment was more dependent on 5-HT availability than successful longterm prophylaxis with lithium. This implies a strong influence of 'state' variables on vulnerability to ATD in BD patients. However previous studies on ATD in BD patients did not include healthy subjects as a control group and drawing conclusions about 'trait' influence on mood changes following ATD is therefore hampered.
ATD-induced mood lowering in depressed patients and their first-degree relatives suggest central serotonergic vulnerability (Klaassen et al. 1999; Delgado et al. 1991) . We suggest that mood changes after ATD in FH II subjects might be explained by the same vulnerability. The discrepancy that FH II of BD patients report an increase in mood, whereas relatives of unipolar patients report a decrease in mood, may possibly be due to vulnerability to mania in FH II subjects. Both mania and depression have been associated with hyposerotonergic activity (Goodwin and Ghaemi 1990; Price et al. 1990; Young et al. 1994) .
Suicide has also been associated with low central 5-HT (Pfeffer et al. 1998; Asberg 1997) . Meltzer et al. (1984) described an increased serotonergic vulnerability in depressed patients with a history of suicidal activity. Higher rates of suicide has been described in BD type II compared with BD type I patients (Rihmer and Pestality 1999) . It is speculated that suicide is another independent factor which may contribute to serotonergic vulnerability in BD type II psychophysiology.
Compared with controls, FH I subjects did not show mood changes after ATD, which may suggest a biological distinction between BD type I and type II. FH I subjects are characterized by cognitive deficits (Sobczak et al. (Krabbendam et al. 2000) . Cognitive deficits have been described in FH I and not in FH II subjects (Sobczak et al. 2002) . It was suggested that BD type I subjects share more similarities with a primary psychotic spectrum whereas BD type II is characterized by primary affective symptoms. This hypothesis appears to be consistent with the absence of mood changes observed in schizophrenic patients after ATD (Sharma et al. 1997 ). Inconsistent findings of previous studies on ATD in BD may possibly be due to a failure to take differences in BD type I and BD type II into account. The significant decrease in cortisol release in FH subjects following ATD suggests a 5-HT vulnerability in FH subjects affecting the HPA-axis. Decrease in cortisol response is consistent with previous described changes in 5-HT responsivity in BD (Vieta et al. 1999) . A blunted cortisol response has been described in BD compared with controls following intravenous Trp challenge (Nurnberger et al. 1990 ).
ATD-induced blunted cortisol response might have been attenuated due to the weak stress-inducing effect of the SIST procedure. The cortisol peak after the SIST (21%) was modest compared with the previously reported (Ϯ) 90% increase in saliva cortisol concentrations (van Eck et al. 1996) possibly due to procedural differences in our experiment. First, we used a modified and perhaps less stressful version of the SIST; in the study by van Eck et al. (1996) , subjects were unaware that they would be asked to deliver a speech. Second, our subjects underwent the SIST 3 times: once as a training procedure, once after ATD, and once after placebo.
The ATD-induced mood changes are not likely to be attributable to changes in cortisol release. First, correlation analyses revealed no significant association. Second, the reported mood changes were specific for FH II subjects, whereas the cortisol response did not differ between FH I or FH II subjects. Third, mood ratings showed no differences between assessments immediately before and after the SIST.
In conclusion, this study provides evidence for 5-HT vulnerability affecting the HPA-axis and mood in FH subjects. The 5-HT vulnerability affecting mood was present only in FH II subjects and not in FH I subjects. This is consistent with a primarily psychotic psychopathology in BD type I and a primarily affective psychopathology in BD type II patients.
These findings should be replicated in a larger research population with BD type I and type II patients as well as their relatives.
